HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity.

AbstractINTRODUCTION:
Survival of Hodgkin lymphoma (HL) patients has significantly improved in recent decades. The current first-line therapy is doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) ± irradiation and may cause pulmonary toxicity. Strategies to reduce late toxicity as well as increase survival rate are of interest.
PATIENTS AND METHODS:
Pulmonary function of previously treated HL patients was collected over a 12-month period using St. George Respiratory Questionnaire (SGRQ), chest X-ray, dynamic inhalation lung scintigraphy and spirometry.
RESULTS:
A total of 137 patients' data were reviewed. Median time elapsed since diagnosis was 11 years (range was 2 - 30 years). Chest irradiation did not significantly worsen pulmonary function. Number of ABVD cycles with consequential bleomycin dose showed significant correlation with SGRQ total score in patients receiving ABVD plus chest irradiation (p = 0.01). Scintigraphy results correlated with bleomycin dose in patients receiving ABVD without chest irradiation (right side: p = 0.099, left side: p = 0.051).
DISCUSSION:
An additive negative effect of chest irradiation was not confirmed as reflected in the literature; however, increasing cumulative bleomycin dose worsened pulmonary function.
AuthorsÁdám Jóna, Zsófia Miltényi, Zsófia Ujj, Ildikó Garai, Mária Szilasi, Árpád Illés
JournalExpert opinion on drug safety (Expert Opin Drug Saf) Vol. 13 Issue 10 Pg. 1291-7 (Oct 2014) ISSN: 1744-764X [Electronic] England
PMID25135756 (Publication Type: Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Bleomycin
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
  • Bleomycin (administration & dosage, adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Female
  • Hodgkin Disease (drug therapy)
  • Humans
  • Lung Diseases (chemically induced, epidemiology, physiopathology)
  • Male
  • Middle Aged
  • Respiratory Function Tests
  • Retrospective Studies
  • Surveys and Questionnaires
  • Time Factors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: